Published in

Wiley, Arthritis and Rheumatism, 7(48), p. 1781-1787, 2003

DOI: 10.1002/art.11087

Links

Tools

Export citation

Search in Google Scholar

Assessing the efficacy and safety of rheumatic disease treatments: Obstacles and proposed solutions

Journal article published in 2003 by David T. Felson ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Although both the entrepreneurial spirit of individual investigators and development of new therapies by the pharmaceutical industry need vigorous encouragement, we can no longer rely completely on information provided by these sources to determine how well treatments work and which ones work best. Enumeration of problems described above leads naturally to suggested specific solutions; I acknowledge that medical editors, especially, have moved toward adoption of some of them. However, none of the suggested solutions has been broadly and successfully adopted, and without a concerted effort, especially by medical editors, these problems will remain, and information about the efficacy and safety of treatments will be incomplete and, in some cases, inaccurate. Although the proposed solutions (Table 2) represent small steps toward the ideal state described earlier, most of them will not be easily accomplished, and other approaches certainly exist. Nonetheless, I believe that consideration of these issues is timely, and that a debate regarding possible solutions is warranted.